India, Nov. 10 -- Esperion Therapeutics (ESPR), now wholly owned by ARCHIMED, announced a settlement agreement with Aurobindo Pharma resolving patent litigation related to the cholesterol-lowering medicines NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe).
The dispute arose after Aurobindo filed abbreviated new drug applications (ANDAs) seeking approval to market generic versions of the two products in the United States before the expiration of Esperion's patents.
Under the settlement agreement, Aurobindo has agreed not to market generic versions of NEXLETOL or NEXLIZET in the U.S. before April 19, 2040, unless certain customary expectations specified in the agreement occur.
The agreement resolves Esperion's patent l...